You are here

gilteritinib

Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo

Endpoints

Fri, 09/20/19 - 10:40 pm

FDA stamps fast OK on Astellas' pioneering FLT3 AML drug gilteritinib, expanding on a record year for new approvals

Endpoints

Thu, 11/29/18 - 12:10 am